Keyphrases
Adoptive Cell Therapy
31%
Anticancer Immunotherapy
13%
Antiphospholipid Syndrome
13%
Autoantibodies
15%
Biomarker Profile
27%
CCL18
19%
Co-culture System
13%
Connective Tissue Disease
13%
CXCL10
44%
Disease Activity
44%
Endothelial Cells
18%
Endothelial Dysfunction
16%
Galectin-9 (Gal-9)
47%
High-risk Neuroblastoma
27%
Immunomodulatory
21%
Inflammation
16%
Integrative Analysis
27%
Interferon Signature
31%
Juvenile Dermatomyositis
87%
Killing Assay
18%
Localized Scleroderma
19%
Materno-fetal Interface
13%
MHC Class II
35%
Midkine
13%
Natural Killer Cells
26%
Nectin-2
27%
Neuroblastoma
98%
Organoids
51%
Patient-derived Organoids
17%
Pediatric
17%
Pediatric Tumors
16%
Personalised Assessment
13%
Serum Levels
17%
Siglec
13%
Single-cell RNA Sequencing (scRNA-seq)
30%
Solid Tumors
16%
Specific Adaptation
13%
STAT3 mutation
13%
Systemic Autoimmune Diseases
16%
T Cells
73%
T-cell Mediated
14%
Three-dimensional Modeling
13%
TIGIT
28%
Tissue Inflammation
16%
Tissue Residency
14%
TNF Receptor 2 (TNFR2)
20%
Treatment Response
27%
Tumor
24%
Tumor Cells
22%
Working Diagnosis
16%
Immunology and Microbiology
5' Nucleotidase
13%
Antiphospholipid Syndrome
13%
Autoantibodies
19%
Autoimmunity
13%
B Cell
9%
Blood Level
20%
CCL18
19%
CD69
12%
Cell Interaction
13%
Cell Lineage
13%
Coculture
8%
Connective Tissue
13%
CXCL10
22%
CXCL13
9%
Cytotoxicity
35%
Dermatomyositis
82%
Ecalectin
33%
Eosinophilic Fasciitis
11%
Galectin 1
9%
Immunity
16%
Immunoassay
7%
Immunogenicity
13%
Immunology
8%
Immunosuppressive Drug
13%
Immunotherapy
61%
interferon
42%
Localized Scleroderma
19%
Major Histocompatibility Complex
11%
Midkine
13%
Migration Inhibition Factor
13%
Myeloid
9%
Myositis
8%
Natural Killer Cell
26%
Natural Killer T Cell
9%
Organoid
52%
Oxygen Consumption
13%
Prednisone
13%
Programmed Death-Ligand 1
13%
Regulatory T Cell
13%
RNA Sequence
28%
Sialoadhesin
13%
STAT3
13%
Survival Rate
10%
Syngenic
9%
Systemic Autoimmune Disease
15%
Systemic Lupus Erythematosus
13%
T Cell
88%
T Cell Receptor
23%
Tumor Cell
26%
Tumor Necrosis Factor Receptor 2
16%
Medicine and Dentistry
B Cell
5%
Cardiorespiratory
13%
Cell Lineage
13%
Cell Therapy
31%
Chemotherapy
10%
Childhood Cancer
15%
Cytotoxicity
18%
Cytotoxicity Assay
13%
Dinutuximab
9%
Ex Vivo
5%
Ganglioneuroblastoma
100%
Histone Deacetylase Inhibitor
8%
Immunity
20%
Immunocompetent Cell
7%
Immunogenicity
15%
Immunosuppressive Drug
11%
Immunotherapy
83%
In Vitro
25%
Juvenile Dermatomyositis
13%
Major Histocompatibility Complex
10%
Midkine
13%
Migration Inhibition Factor
13%
Natural Killer Cell
23%
Natural Killer Cell
5%
Neoplasm
32%
Neuroblastoma Cell
5%
Neuroblastoma Cell Line
5%
Organoid
64%
Pediatric Cancer
11%
Pediatrics
15%
Pediatrics Patient
5%
Pontine Glioma
13%
Programmed Death-Ligand 1
7%
RNA Sequence
28%
Secretion (Process)
7%
Side Effect
5%
Solid Malignant Neoplasm
30%
Survival Rate
7%
T Cell
79%
T Cell Receptor
6%
T Lymphocyte Receptor
14%
Tumor Cell
26%
Tumor Infiltrating Lymphocyte
5%
Tumor Microenvironment
13%
